ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)

US00653A1079 - ADR

0.5851  -0.02 (-3.27%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADAP. ADAP was compared to 565 industry peers in the Biotechnology industry. ADAP has a bad profitability rating. Also its financial health evaluation is rather negative. ADAP is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADAP has reported negative net income.
In the past year ADAP has reported a negative cash flow from operations.
In the past 5 years ADAP always reported negative net income.
In the past 5 years ADAP reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -14.02%, ADAP belongs to the top of the industry, outperforming 84.70% of the companies in the same industry.
With a decent Return On Equity value of -55.65%, ADAP is doing good in the industry, outperforming 63.88% of the companies in the same industry.
Industry RankSector Rank
ROA -14.02%
ROE -55.65%
ROIC N/A
ROA(3y)-41.42%
ROA(5y)-45.74%
ROE(3y)-188.98%
ROE(5y)-143.21%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ADAP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADAP has more shares outstanding
Compared to 5 years ago, ADAP has more shares outstanding
There is no outstanding debt for ADAP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.27, we must say that ADAP is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.27, ADAP perfoms like the industry average, outperforming 46.98% of the companies in the same industry.
ADAP has a Debt/Equity ratio of 0.62. This is a neutral value indicating ADAP is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.62, ADAP is doing worse than 75.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z -3.27
ROIC/WACCN/A
WACC9.06%

2.3 Liquidity

A Current Ratio of 3.85 indicates that ADAP has no problem at all paying its short term obligations.
ADAP has a Current ratio (3.85) which is in line with its industry peers.
A Quick Ratio of 3.82 indicates that ADAP has no problem at all paying its short term obligations.
With a Quick ratio value of 3.82, ADAP perfoms like the industry average, outperforming 47.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.85
Quick Ratio 3.82

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.54% over the past year.
Looking at the last year, ADAP shows a very strong growth in Revenue. The Revenue has grown by 146.26%.
Measured over the past years, ADAP shows a small growth in Revenue. The Revenue has been growing by 0.26% on average per year.
EPS 1Y (TTM)68.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
Revenue 1Y (TTM)146.26%
Revenue growth 3Y147.83%
Revenue growth 5Y0.26%
Sales Q2Q%458.83%

3.2 Future

Based on estimates for the next years, ADAP will show a small growth in Earnings Per Share. The EPS will grow by 1.81% on average per year.
The Revenue is expected to grow by 22.91% on average over the next years. This is a very strong growth
EPS Next Y75.42%
EPS Next 2Y15.6%
EPS Next 3Y13.77%
EPS Next 5Y1.81%
Revenue Next Year123.73%
Revenue Next 2Y-30.12%
Revenue Next 3Y-8.5%
Revenue Next 5Y22.91%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADAP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ADAP's earnings are expected to grow with 13.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.6%
EPS Next 3Y13.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (12/23/2024, 11:37:28 AM)

0.5851

-0.02 (-3.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners61.77%
Inst Owner Change-1.52%
Ins Owners0.28%
Ins Owner Change0%
Market Cap149.72M
Analysts77.33
Price Target2.31 (294.8%)
Short Float %2.64%
Short Ratio3.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)260.34%
Min EPS beat(2)92.37%
Max EPS beat(2)428.3%
EPS beat(4)2
Avg EPS beat(4)76.33%
Min EPS beat(4)-135.29%
Max EPS beat(4)428.3%
EPS beat(8)4
Avg EPS beat(8)40.79%
EPS beat(12)5
Avg EPS beat(12)1.24%
EPS beat(16)7
Avg EPS beat(16)0.77%
Revenue beat(2)2
Avg Revenue beat(2)218.16%
Min Revenue beat(2)177.41%
Max Revenue beat(2)258.91%
Revenue beat(4)2
Avg Revenue beat(4)74.51%
Min Revenue beat(4)-98.89%
Max Revenue beat(4)258.91%
Revenue beat(8)4
Avg Revenue beat(8)154.26%
Revenue beat(12)6
Avg Revenue beat(12)100.06%
Revenue beat(16)7
Avg Revenue beat(16)75.48%
PT rev (1m)-11.63%
PT rev (3m)-11.63%
EPS NQ rev (1m)-16.67%
EPS NQ rev (3m)-14.84%
EPS NY rev (1m)58.97%
EPS NY rev (3m)64.91%
Revenue NQ rev (1m)-51.7%
Revenue NQ rev (3m)-61.07%
Revenue NY rev (1m)8.83%
Revenue NY rev (3m)12.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.86
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.98
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.68
BVpS0.31
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.02%
ROE -55.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.42%
ROA(5y)-45.74%
ROE(3y)-188.98%
ROE(5y)-143.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.11%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.85
Quick Ratio 3.82
Altman-Z -3.27
F-Score4
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)224.13%
Cap/Depr(5y)149.8%
Cap/Sales(3y)86.8%
Cap/Sales(5y)121.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95%
EPS Next Y75.42%
EPS Next 2Y15.6%
EPS Next 3Y13.77%
EPS Next 5Y1.81%
Revenue 1Y (TTM)146.26%
Revenue growth 3Y147.83%
Revenue growth 5Y0.26%
Sales Q2Q%458.83%
Revenue Next Year123.73%
Revenue Next 2Y-30.12%
Revenue Next 3Y-8.5%
Revenue Next 5Y22.91%
EBIT growth 1Y67.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-443.34%
OCF growth 3YN/A
OCF growth 5YN/A